Currently, BH3 mimetics targeting MCL1, including AMG176, S63845, and AZD5991, are becoming available and may have single-agent activity in certain subsets of tumors, but their efficacy in PC may still require combination therapy (Arai et al., 2020; Arai et al., 2018). Here, MCL1 is linked to pachyonychia congenita.